Elevated SLC3A2 associated with poor prognosis and enhanced malignancy in gliomas

Area of Science:

• Neuro-oncology
• Molecular Biology
• Cancer Genomics

Background:

• The role of SLC3A2 (solute carrier family 3 member 2), implicated in disulfidptosis, remains uncharacterized in gliomas.
• Gliomas are primary brain tumors with significant morbidity and mortality, necessitating novel prognostic markers.

Purpose of the Study:

• To elucidate the prognostic value and functional role of SLC3A2 in glioma.
• To investigate the association between SLC3A2 expression and the tumor microenvironment, including immune infiltration and therapeutic indicators.

Main Methods:

• Bioinformatic analysis of public databases and clinical glioma samples.
• Meta-analysis and Cox regression for prognostic evaluation.
• In vitro (CCK8, colony formation, migration, invasion assays) and in vivo (orthotopic xenograft model) functional studies.
• Assessment of immune infiltration (CIBERSORT, ssGSEA, single-cell sequencing), TIDE, and EMT scores.

Main Results:

• High SLC3A2 expression is linked to adverse clinicopathological features and poorer patient survival.
• Upregulated SLC3A2 promotes tumor migration, invasion, and alters immune cell infiltration, particularly macrophages.
• SLC3A2 expression correlates with immune checkpoints and TIDE, suggesting a role in immune response.
• Knockdown of SLC3A2 reduced glioma cell proliferation, migration, invasion in vitro and suppressed tumor growth in vivo.

Conclusions:

• SLC3A2 serves as an independent prognostic biomarker for glioma.
• SLC3A2 significantly influences glioma progression and the tumor immune microenvironment.
• Targeting SLC3A2 may offer a potential therapeutic strategy for glioma.